Blood Cancer Drugs Market by Drug Type – Adcetris (brentuximab vedotin), Gleevec/Glivec (Imatinib), Imbruvica (ibrutinib), Kyprolis (carfilzomib), Pomalyst (pomalidomide), Revlimid (lenalidomide), Rituxan/Mabthera (rituximab), Tasigna (nilotinib), Velcade (bortezomib), Vidaza (azacitidine), Others and Forecast 2017-2021

Blood Cancer Drugs Market by Drug Type – Adcetris (brentuximab vedotin), Gleevec/Glivec (Imatinib), Imbruvica (ibrutinib), Kyprolis (carfilzomib), Pomalyst (pomalidomide), Revlimid (lenalidomide), Rituxan/Mabthera (rituximab), Tasigna (nilotinib), Velcade (bortezomib), Vidaza (azacitidine), Others and Forecast 2017-2021

Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced. According to American Cancer Society (2015), each year, more than 162,000 Americans are diagnosed with a blood cancer accounting for more than 9% of all new cancer diagnoses. Major types of blood cancers include leukemia, lymphoma and myeloma. Treatment for blood cancer depends on the type of cancer, age, cancer progression rate, extent of cancer spread and other factors. A range of approved targeted therapies for Chronic Lymphocytic Leukemia (CLL) includes monoclonal antibodies and B-cell receptor pathway inhibitors, that treat the root cause of the disease with fewer risks to the immune system and often result in remission. In addition, combinations of these targeted therapies are being explored providing potential new treatment options for CLL patients with fewer side effects. There are additional targeted therapies for Chronic Myeloid Leukemia (CML) that are able to effectively treat many of the identified mutated forms of CML by disrupting signals that lead to cancer cell growth. Many of the medicines in the pipeline are building on novel scientific approaches and looking at new ways to treat blood cancers. Almost 40 percent of the new anticancer drugs developed since 2000 were first approved for blood cancer patients, and are now helping patients with other cancers and chronic diseases.

The global blood cancer drugs market segmentation is based on drug Types – Adcetris (brentuximab vedotin), Gleevec/Glivec (Imatinib), Imbruvica (ibrutinib), Kyprolis (carfilzomib), Pomalyst (pomalidomide), Revlimid (lenalidomide), Rituxan/Mabthera (rituximab), Tasigna (nilotinib), Velcade (bortezomib), Vidaza (azacitidine), and Others.

The global blood cancer drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global blood cancer drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global blood cancer drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global blood cancer drugs market and profiled in this report include AbbVie, Inc., Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, and Pfizer, Inc.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Blood Cancer Drugs Market

1. Drug Type
1.1. Adcetris (brentuximab vedotin)
1.2. Gleevec/Glivec (Imatinib)
1.3. Imbruvica (ibrutinib)
1.4. Kyprolis (carfilzomib)
1.5. Pomalyst (pomalidomide)
1.6. Revlimid (lenalidomide)
1.7. Rituxan/Mabthera (rituximab)
1.8. Tasigna (nilotinib)
1.9. Velcade (bortezomib)
1.10. Vidaza (azacitidine)
1.11. Others

2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.3. Latin America (Brazil, Mexico, Rest of LA)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World (Middle East & Africa)

3. Company Profiles
3.1. AbbVie, Inc.
3.2. Bristol-Myers Squibb Company
3.3. Celgene Corporation
3.4. F. Hoffmann-La Roche Ltd.
3.5. GlaxoSmithKline plc
3.6. Johnson & Johnson
3.7. Pfizer, Inc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish